Kalbe Farma stock holds steady as investors watch earnings and margin trends

Published on 09/05/2026 at 06:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kalbe Farma stock is trading sideways on the Indonesia Stock Exchange as investors focus on recent earnings trends, margin developments and the broader healthcare demand backdrop in Indonesia.

Kalbe Farma, ID1000096605, Illustration mit AI erstellt.

Kalbe Farma stock is quoted at 775 Indonesian rupiah on the Indonesia Stock Exchange, with the latest close reported on September 4, 2026, implying a modest daily move of around 0.6 percent according to market data for KLBF.JK.

Earnings trajectory and profitability

Kalbe Farma, a leading Indonesian pharmaceutical and healthcare company (ISIN ID1000096605), has recently reported its latest interim financial results for fiscal year 2026, which investors use to gauge the company’s earnings power and margin resilience in a competitive market.

In its most recent reported quarter of fiscal year 2026, Kalbe Farma generated multi-trillion rupiah revenue and remained profitable, reflecting continued demand for prescription drugs, consumer health products and nutritional supplements in Indonesia, even as input costs and currency fluctuations influence margins.

Market positioning in Indonesian healthcare

With a broad portfolio in prescription pharmaceuticals, over-the-counter medicines, nutritionals and medical devices, Kalbe Farma benefits from structural growth in Indonesia’s healthcare spending and a large domestic population, providing a supportive backdrop for long-term revenue expansion.

For investors, the balance between volume growth and pricing power is crucial: higher sales in key therapeutic areas and nutritional categories help offset regulatory pressures on drug prices and rising operating expenses, supporting Kalbe Farma’s operating margin in recent quarters of fiscal year 2026.

Go deeper

Further information on Kalbe Farma

More detailed data on Kalbe Farma’s stock, key figures and corporate disclosures can be found in the dedicated topic overview and on the company’s investor relations pages.

All news on this ISIN Investor Relations

Representative product: nutritional and consumer health lines

One representative revenue pillar for Kalbe Farma is its consumer health and nutritional products segment, which includes vitamins, supplements and functional nutrition items that cater to Indonesia’s growing middle class and aging population.

Stock level and investor perspective

Kalbe Farma stock closed at 775 rupiah on September 4, 2026, on the Indonesia Stock Exchange, with the quotation for KLBF.JK reflecting a stable share price in recent sessions amid broader moves in Indonesian equities.